文献速递妇科

伊立替康联合贝伐珠单抗治疗复发性卵巢癌的II期研究

Phase II study of irinotecan in combination with bevacizumab in recurrent ovarian cancer.
PubMed 文献 · Gynecol Oncol · 2016-12-05

该II期研究评估伊立替康联合贝伐珠单抗治疗复发性卵巢癌的疗效与安全性,主要终点为6个月无进展生存率。29例患者入组,6个月PFS率为55.2%,中位PFS 6.8个月,中位OS 15.4个月,客观缓解率27.6%,最常见3/4级毒性为腹泻,未观察至治疗相关死亡。

要点

  • 6个月无进展生存率为55.2%(95%CI 40%-77%),中位PFS 6.8个月(95%CI 5.1-12.1个月)。
  • 客观缓解率27.6%(95%CI 12.7%-47.2%),临床获益率72.4%(95%CI 52.8%-87.3%)。
  • 最常见3/4级毒性为腹泻,未观察至治疗相关死亡。

核心结论

  • 伊立替康联合贝伐珠单抗在经重度治疗的复发性卵巢癌患者中具有活性,包括既往使用过贝伐珠单抗和拓扑异构酶抑制剂者。

研究设计与样本

  • II期研究,纳入复发性卵巢癌患者,既往治疗线数不限。
  • 伊立替康250mg/m2(前6例患者毒性评估后改为175mg/m2)联合贝伐珠单抗15mg/kg,每3周给药直至疾病进展或毒性。
  • 每2周期采用RECIST或CA-125标准评估疗效。
  • 共29例患者入组,其中铂敏感10例,铂耐药19例。

主要发现

  • 既往治疗方案中位数为5线(范围1-12线);13例既往使用过贝伐珠单抗,11例既往使用过拓扑替康。
  • 6个月无进展生存率为55.2%(95%CI:40%-77%)。
  • 中位无进展生存期6.8个月(95%CI:5.1-12.1个月);中位总生存期15.4个月(95%CI:11.9-20.4个月)。
  • 本研究未观察到完全缓解;全部患者客观缓解率(部分缓解或完全缓解)为27.6%(95%CI:12.7%-47.2%),临床获益率(完全缓解+部分缓解+疾病稳定)为72.4%(95%CI:52.8%-87.3%);12例患者缓解持续时间超过6个月。
  • 在24例可测量疾病患者中,8例(30%)记录到部分缓解;13例在首次评估时维持疾病稳定。

临床怎么用

  • 作者结论认为伊立替康联合贝伐珠单抗在经重度治疗的复发性卵巢癌患者中具有活性,包括既往使用过贝伐珠单抗和拓扑异构酶抑制剂者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate the efficacy and safety of irinotecan and bevacizumab in recurrent ovarian cancer. The primary objective was to estimate the progression free survival (PFS) rate at 6months. Secondary objectives included estimation of overall survival (OS), objective response rate (ORR), duration of response, and an evaluation of toxicity. METHODS: Recurrent ovarian cancer patients with no limit on prior treatments were eligible. Irinotecan 250mg/m2 (amended to 175mg/m2 after toxicity assessment in first 6 patients) and bevacizumab 15mg/kg were administered every 3weeks until progression or toxicity. Response was assessed by RECIST or CA-125 criteria every 2cycles. RESULTS: Twenty nine patients enrolled (10 were platinum-sensitive and 19 were platinum-resistant). The median number of prior regimens was 5 (range 1-12); 13 patients had prior bevacizumab and 11 prior topotecan. The PFS rate at 6months was 55.2% (95% CI: 40%-77%). The median number of study cycles given was 7 (range 1-34). Median PFS was 6.8months (95% CI: 5.1-12.1months); median OS was 15.4months (95% CI: 11.9-20.4months). In this study, no complete response (CR) was observed. The objective response rate (ORR; PR or CR) for all patients entered was 27.6% (95% CI: 12.7%-47.2%) and the clinical benefit rate (CR+PR+SD) was 72.4% (95% CI: 52.8%-87.3%); twelve patients experienced duration of response longer than 6months. In the 24 patients with measurable disease, a partial response (PR) was documented in 8 (30%) patients; 13 patients maintained stable disease (SD) at first assessment. The most common grade 3/4 toxicity was diarrhea. No treatment-related deaths were observed. CONCLUSIONS: Irinotecan and bevacizumab has activity in heavily pre-treated patients with recurrent ovarian cancer, including those with prior bevacizumab and topoisomerase inhibitor use.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Musa F, Pothuri B, Blank SV, et al. Phase II study of irinotecan in combination with bevacizumab in recurrent ovarian cancer. Gynecol Oncol. 2016. PMID: 27931751. doi:10.1016/j.ygyno.2016.11.043

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。